Sekeres, M. A., Kalaycio, M. E., Erba, H. P., Sobecks, R., Advani, A., Chan, J., & Maciejewski, J. P. (2007). P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS. In Leukemia Research (Vol. 31, pp. S125–S125). Elsevier BV. https://doi.org/10.1016/s0145-2126(07)70225-4

Sekeres, M. A., M. E. Kalaycio, H. P. Erba, R. Sobecks, A. Advani, J. Chan, and J. P. Maciejewski. “P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS.” In Leukemia Research, 31:S125–S125. Elsevier BV, 2007. https://doi.org/10.1016/s0145-2126(07)70225-4.

Sekeres MA, Kalaycio ME, Erba HP, Sobecks R, Advani A, Chan J, et al. P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS. In: Leukemia Research. Elsevier BV; 2007. p. S125–S125.

Sekeres, M. A., et al. “P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS.” Leukemia Research, vol. 31, Elsevier BV, 2007, pp. S125–S125. Crossref, doi:10.1016/s0145-2126(07)70225-4.

Sekeres MA, Kalaycio ME, Erba HP, Sobecks R, Advani A, Chan J, Maciejewski JP. P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS. Leukemia Research. Elsevier BV; 2007. p. S125–S125.